Europe Epilepsy Drugs Market
No. of Pages: 74 | Report Code: BMIRE00029809 | Category: Life Sciences
No. of Pages: 74 | Report Code: BMIRE00029809 | Category: Life Sciences
Epilepsy is one of the prevalent neurological disorders affecting the geriatric population. According to the National Center for Biotechnology Information, epilepsy is the third most common neurological disorder affecting the elderly after dementia and stroke. The incidence of epilepsy is increasing in older adults, partly because of the growing prevalence of stroke, brain tumors, and dementia. Considering that modern society is aging, the overall prevalence and incidence of epilepsy are expected to rise.
The Eurostat statistics indicate that over one-fifth (21.1%) of the European population was aged 65 or more in 2022. According to an article published by UpToDate Inc. in August 2021, the incidence rate of epilepsy rises with age and is highest among patients aged 75 and above.
Therefore, due to the growing geriatric population, there is notable surge in conditions such as epilepsy owing to which the market for epilepsy drugs witnesses a significant growth.
The Europe epilepsy drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy drugs market. The European epilepsy drugs market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.
The Europe epilepsy drugs market is segmented into treatment, distribution channel and country.
Based on treatment, the Europe epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.
In terms of distribution channel, the Europe epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.
Based on country, the Europe epilepsy drugs market is segmented Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy drugs market in 2022.
Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA are some of the leading companies operating in the Europe epilepsy drugs market.
Strategic insights for the Europe Epilepsy Drugs provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,941.16 Million |
| Market Size by 2030 | US$ 2,626.05 Million |
| Global CAGR (2022 - 2030) | 3.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Epilepsy Drugs refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
1. Abbott Laboratories
2. Alkem Laboratories Ltd
3. GSK Plc
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Teva Pharmaceutical Industries Ltd
8. UCB SA
The Europe Epilepsy Drugs Market is valued at US$ 1,941.16 Million in 2022, it is projected to reach US$ 2,626.05 Million by 2030.
As per our report Europe Epilepsy Drugs Market, the market size is valued at US$ 1,941.16 Million in 2022, projecting it to reach US$ 2,626.05 Million by 2030. This translates to a CAGR of approximately 3.8% during the forecast period.
The Europe Epilepsy Drugs Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Epilepsy Drugs Market report:
The Europe Epilepsy Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Epilepsy Drugs Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Epilepsy Drugs Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Epilepsy Drugs Market
